These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 9457399)
1. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399 [TBL] [Abstract][Full Text] [Related]
2. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Yang JC; Rosenberg SA Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400 [TBL] [Abstract][Full Text] [Related]
3. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma]. Atzpodien J; Kirchner H; Poliwoda H Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118 [TBL] [Abstract][Full Text] [Related]
4. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
8. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S; Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438 [TBL] [Abstract][Full Text] [Related]
9. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389 [TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J; J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421 [TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. Hofmockel G; Langer W; Theiss M; Gruss A; Frohmüller HG J Urol; 1996 Jul; 156(1):18-21. PubMed ID: 8648791 [TBL] [Abstract][Full Text] [Related]
13. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901 [TBL] [Abstract][Full Text] [Related]
14. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820 [TBL] [Abstract][Full Text] [Related]
15. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Bukowski RM Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000. Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011 [TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727 [TBL] [Abstract][Full Text] [Related]
19. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Atzpodien J; Kirchner H; Illiger HJ; Metzner B; Ukena D; Schott H; Funke PJ; Gramatzki M; Jürgenson S; Wandert T; Patzelt T; Reitz M Br J Cancer; 2001 Oct; 85(8):1130-6. PubMed ID: 11710825 [TBL] [Abstract][Full Text] [Related]
20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]